Details of Disease

General Information of Disease (ID: DISCDP7W)

Disease Name Haematological malignancy
Synonyms
hematological tumor; hematopoietic tumor; haematopoietic tumour; malignant haematopoietic neoplasm; hematological neoplasm; hematopoietic, Including myeloma; malignant hematopoietic neoplasm; haematopoietic cell tumour; hematopoietic and lymphoid cell neoplasm; haematopoietic cancer; haematopoietic and lymphoid neoplasms; haematological neoplasm; hematopoietic malignancy, NOS; hematopoietic neoplasm; HEMOLYMPHORETICULAR tumor, malignant; hematologic cancer; hematopoietic and lymphoid neoplasms; hematopoietic cell tumor; malignant hematologic neoplasm; hematopoietic neoplasms including lymphomas; hematologic malignancy; haematopoietic neoplasms including lymphomas; haematopoietic malignancy, NOS; haematopoietic neoplasm; hematopoietic cancer; hematologic neoplasm; haematological tumour
Disease Class 2B33: Malignant haematopoietic neoplasm
Definition
A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.
Disease Hierarchy
DISTBY9Z: Tumour
DISNCK1H: Haematopoietic/lymphoid cancer
DISCDP7W: Haematological malignancy
ICD Code
ICD-11
ICD-11: 2B33.Y
Disease Identifiers
MONDO ID
MONDO_0044881
MESH ID
D019337
UMLS CUI
C0376544
MedGen ID
91264
SNOMED CT ID
414388001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 8 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Atezolizumab DMMF8U0 Approved Monoclonal antibody [1]
Bavencio DMU9C8F Approved Monoclonal antibody [1]
Fludarabine DMVRLT7 Approved Small molecular drug [2]
Ivosidenib DM8S6T7 Approved NA [3]
Moxetumomab pasudotox DMN63DZ Approved Monoclonal antibody [4]
Obinutuzumab DM3BVAE Approved Antibody [5]
Polatuzumab vedotin DMF6Y0L Approved Antibody [5]
Rituximab DM1YVZT Approved Antibody [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)
This Disease is Treated as An Indication in 1 Approved
Drug Name Drug ID Highest Status Drug Type REF
Relatlimab DM28AZV Approved NA [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 80 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cresemba DMKA7H3 Phase 3 NA [1]
DSP-7888 DM781D6 Phase 3 Vaccine [7]
Napabucasin DMDZ6Q3 Phase 3 NA [1]
RG7388 DMF5GZI Phase 3 Small molecular drug [8]
Serelsa DMMQ6M1 Phase 3 NA [9]
TZ101 DM5KVMP Phase 3 NA [10]
Ulocuplumab DM6PMNR Phase 3 Monoclonal antibody [11]
ABT-348 DMMZOYN Phase 2 Small molecular drug [12]
ALRN-6924 DMLBWT1 Phase 2 NA [1]
CLR-131 DMDM2DF Phase 2 NA [1]
GS-9973 DMKWCTR Phase 2 Small molecular drug [1]
MDX-1097 DMCK8SX Phase 2 Antibody [13]
Oprozomib DM16RIC Phase 2 Small molecular drug [14]
PDX-101 DM6OC53 Phase 2 Small molecular drug [1]
Radretumab DMSDIDR Phase 2 Monoclonal antibody [15]
RG7596 DMVXGU0 Phase 2 NA [16]
TAK-659 DMJH3U0 Phase 2 NA [17]
ASC-101 DMVNCSK Phase 1/2 NA [18]
AZD9150 DMFQXIP Phase 1/2 NA [19]
BMS-863233 DM5HUY8 Phase 1/2 Small molecular drug [20]
BSK01 DM9S4SB Phase 1/2 NA [1]
DCC-3014 DMHW289 Phase 1/2 Small molecular drug [1]
EDO-S101 DMI71FN Phase 1/2 NA [1]
F-16-131I DM49BX1 Phase 1/2 Antibody [21]
FF-10501-01 DM0HSJK Phase 1/2 NA [22]
HSC835 DMNW27M Phase 1/2 NA [23]
KB-004 DM5U3IF Phase 1/2 Antibody [24]
KiroVAX-001 DMKC1F8 Phase 1/2 NA [7]
KiroVAX-002 DM3NUHJ Phase 1/2 NA [7]
NKR-2 DM2JLCC Phase 1/2 NA [5]
SAR-650984 DMD20YH Phase 1/2 Antibody [25]
SNX-5422 DMIU0VP Phase 1/2 Small molecular drug [1]
TRQ-1501 DM2QS4B Phase 1/2 Cell therapy [26]
YSCMA DMIA9JD Phase 1/2 Antibody [27]
ABBV-621 DM90EO3 Phase 1 Small molecular drug [1]
ALX-0651 DMIRYM8 Phase 1 NA [28]
Anti-CD19 CAR-T cell therapy DMB7JS4 Phase 1 NA [5]
Anti-CD22 DMUFRDK Phase 1 Antibody [29]
APG-1387 DMLEKUY Phase 1 NA [1]
ARQ 621 DMCRLQZ Phase 1 Small molecular drug [30]
ATA520 DMM2VFS Phase 1 NA [1]
AZD4573 DMOYPTK Phase 1 NA [1]
AZD5991 DM7QGHO Phase 1 NA [1]
BAY1251152 DMCJNRL Phase 1 NA [1]
BMS-936561 DMYIBFM Phase 1 NA [31]
BXCL702 DMY9L4C Phase 1 NA [1]
CBLC137 DMY8CZP Phase 1 Small molecular drug [1]
CYAD-01 DMWJRM8 Phase 1 NA [1]
DS-3032 DMA2B5Y Phase 1 NA [1]
EMD-534085 DMQ6YAZ Phase 1 Small molecular drug [32]
ET190 DM7DMR7 Phase 1 NA [1]
FT-1101 DMZOAT3 Phase 1 NA [1]
Gazyva DMV9J0K Phase 1 NA [1]
GS-9901 DMGHN98 Phase 1 NA [33]
GSK3174998 DMDRLHR Phase 1 NA [5]
GSK525762 DMPAWBN Phase 1 Small molecular drug [1]
GSK690693 DMRBVHE Phase 1 Small molecular drug [34]
HDM201 DMVRTCW Phase 1 NA [35]
HGS-1029 DMS9WXG Phase 1 NA [36]
IM19 DM43X0Q Phase 1 CAR T Cell Therapy [37]
IMMU-114 DMTFUM4 Phase 1 Antibody [5]
JNJ-75276617 DMR5RHG Phase 1 Small molecule [38]
JNJ-80948543 DMF6EAZ Phase 1 NA [39]
LOXO-338 DMPX2ZR Phase 1 NA [40]
M7583 DMDK4MG Phase 1 NA [1]
MEDI7247 DM8A3H6 Phase 1 NA [1]
OP-R003 DMH6SNO Phase 1 NA [41]
OPB-111077 DM7YFW5 Phase 1 Small interfering RNA [1]
PLX51107 DMXLHVW Phase 1 NA [1]
R763 DME0CJ9 Phase 1 Small molecular drug [42]
RG6146 DMIHC4R Phase 1 NA [1]
RG7112 DME47TX Phase 1 NA [43]
RG7828 DMCUBZO Phase 1 NA [5]
RGB-286638 DMEGOQP Phase 1 Small molecular drug [44]
SEA-CD40 DM9OVYK Phase 1 NA [5]
SRF231 DM7F90R Phase 1 NA [1]
TAK-901 DM5KDGI Phase 1 Small molecular drug [45]
TAK-940 DM1SNUB Phase 1 CAR-T cell therapy [46]
TTI-621 DMDNPAV Phase 1 Recombinant protein [1]
WT2725 DMUZDFR Phase 1 NA [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 80 Drug(s)
This Disease is Treated as An Indication in 3 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
RG7593 DM32IV4 Discontinued in Phase 2 NA [47]
RG-7356 DMUR6OV Discontinued in Phase 1 Antibody [48]
Wortmannin DM8EVK5 Terminated Small molecular drug [50]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
SGN-19A DMH1WNI Preclinical Antibody [49]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 3 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BAG956 DMWC34B Investigative Small molecular drug [51]
Lactoquinomycin DMZ0O1X Investigative Small molecular drug [51]
PI-103 DMEK4TJ Investigative Small molecular drug [52]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 29 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ABCB1 TT3OT40 Limited Biomarker [53]
FMNL1 TTW20PQ Limited Biomarker [54]
RUNX1 TTWIN3H Limited Biomarker [55]
ABL1 TT6B75U Strong Altered Expression [56]
BCL2A1 TTGT9C7 Strong Altered Expression [57]
CD79B TTBN5I7 Strong Altered Expression [58]
CDK6 TTO0FDJ Strong Altered Expression [59]
EGLN2 TTMHFRY Strong Biomarker [60]
FGF8 TTIUF3J Strong Altered Expression [61]
FLT3 TTGJCWZ Strong Biomarker [62]
HSPA5 TTW26OG Strong Biomarker [63]
HSPB8 TTY0OJN Strong Altered Expression [64]
HTT TTIWZ0O Strong Biomarker [65]
IL21R TTZO9B0 Strong Biomarker [66]
LONP1 TTM1VPZ Strong Altered Expression [67]
MAP3K19 TTRHJA3 Strong Genetic Variation [68]
MYB TT8V13P Strong Altered Expression [69]
PIM1 TTTN5QW Strong Altered Expression [70]
PIM2 TT69J2Z Strong Biomarker [71]
PON1 TT9LX82 Strong Biomarker [72]
PTP4A2 TT1MHKD Strong Biomarker [73]
PTPN7 TT2C1DT Strong Altered Expression [74]
REL TT1ZCTH Strong Genetic Variation [75]
RNASEL TT7V0K4 Strong Biomarker [76]
S1PR2 TTVSMOH Strong Posttranslational Modification [77]
SPN TTOZAX0 Strong Altered Expression [78]
TCL1A TTUKRDV Strong Altered Expression [79]
TRIM28 TTQ2BKV Strong Biomarker [80]
WAS TTE8T73 Strong Genetic Variation [81]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC26A3 DTN1FMD Strong Biomarker [82]
------------------------------------------------------------------------------------
This Disease Is Related to 57 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
JARID2 OT14UM8H Limited Biomarker [83]
KDM2B OTDMCVW7 Limited Biomarker [84]
SOX11 OT4LG7LA Limited Biomarker [85]
TET2 OTKKT03T Limited Biomarker [86]
A4GALT OTPX3UGY Strong Altered Expression [87]
AGFG2 OTXQZHCR Strong Biomarker [88]
AKAP13 OTOZAR14 Strong Biomarker [89]
CBX3 OTOP9RLD Strong Biomarker [90]
CD109 OTDADBM4 Strong Biomarker [91]
CHD8 OTS7A6AF Strong Altered Expression [92]
CIITA OTRJNZFO Strong Biomarker [93]
CLEC2B OT0W0M0L Strong Biomarker [94]
CTNNA1 OTFC725Z Strong Posttranslational Modification [95]
DDX6 OTKWXVDY Strong Genetic Variation [68]
DOCK2 OTZTS3PA Strong Biomarker [96]
ELF4 OT167PR5 Strong Biomarker [97]
ETV6 OTCZMG61 Strong Biomarker [98]
ETV7 OTIAADPA Strong Altered Expression [99]
FIP1L1 OTF91GTL Strong Genetic Variation [100]
GATA2 OTBP2QQ2 Strong Genetic Variation [101]
HIP1 OT7AKCFQ Strong Biomarker [65]
HLA-DPA1 OT7OG7Y2 Strong Genetic Variation [102]
HLA-DPB1 OTW8JHU2 Strong Biomarker [103]
HLA-DRB3 OT5PM9N7 Strong Genetic Variation [102]
HOXB4 OTH1HRW5 Strong Altered Expression [104]
IKZF1 OTCW1FKL Strong Biomarker [105]
KDM3B OTZU5J5S Strong Biomarker [106]
KLRF1 OTGHZ7FU Strong Biomarker [94]
L3MBTL1 OT8M52QY Strong Biomarker [107]
LXN OTZQ2M6Y Strong Altered Expression [108]
MAD2L2 OT24ZO59 Strong Altered Expression [109]
MCM8 OTC93H3S Strong Biomarker [110]
MRO OT5U38CP Strong Altered Expression [58]
MRPL28 OT4LUTZU Strong Biomarker [111]
NAF1 OTMJKJAK Strong Genetic Variation [112]
NFE2L3 OT1MGXT0 Strong Altered Expression [113]
NUP98 OTNT12G2 Strong Biomarker [114]
NXT1 OT0VO6AY Strong Biomarker [111]
PBX1 OTORABGO Strong Biomarker [115]
PCM1 OTFM133C Strong Genetic Variation [116]
PHF6 OT8DXI40 Strong Biomarker [117]
PICALM OTQVRPMQ Strong Biomarker [118]
RGPD2 OTMUZ0HX Strong Biomarker [88]
SAMSN1 OT7N88T1 Strong Biomarker [119]
SETDB1 OTWVUA1B Strong Biomarker [120]
SLU7 OTZUUICN Strong Genetic Variation [121]
SMCHD1 OTBV52DR Strong Biomarker [122]
SNAP91 OTE3EXWZ Strong Biomarker [118]
SRSF3 OTOFT707 Strong Genetic Variation [123]
TCL1B OT4CSO39 Strong Altered Expression [79]
TNIP1 OTRAOTEW Strong Genetic Variation [112]
TSGA10 OTIF1O1T Strong Altered Expression [124]
AVEN OTGIN5YK Definitive Biomarker [125]
BCL11B OT8KKCVJ Definitive Biomarker [126]
BCR OTCN76C1 Definitive Biomarker [127]
MIXL1 OT584VOQ Definitive Altered Expression [128]
PA2G4 OT7IG7HT Definitive Altered Expression [129]
------------------------------------------------------------------------------------
⏷ Show the Full List of 57 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4802).
3 ClinicalTrials.gov (NCT02073994) Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation. U.S. National Institutes of Health.
4 Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 ClinicalTrials.gov (NCT02407080) Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia. U.S. National Institutes of Health.
9 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026785)
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036660)
11 ClinicalTrials.gov (NCT02472977) Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors.
12 ClinicalTrials.gov (NCT02478320) Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors.
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025289)
14 ClinicalTrials.gov (NCT01832727) Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026308)
16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034127)
17 ClinicalTrials.gov (NCT02323113) Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.
19 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8113).
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031840)
22 ClinicalTrials.gov (NCT02193958) Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies. U.S. National Institutes of Health.
23 ClinicalTrials.gov (NCT01930162) Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant. U.S. National Institutes of Health.
24 ClinicalTrials.gov (NCT01211691) Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF). U.S. National Institutes of Health.
25 ClinicalTrials.gov (NCT01084252) Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies. U.S. National Institutes of Health.
26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031210)
28 ClinicalTrials.gov (NCT01374503) First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4. U.S. National Institutes of Health.
29 2011 Pipeline of Seattle Genetics.
30 ClinicalTrials.gov (NCT00825487) Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies. U.S. National Institutes of Health.
31 J Clin Oncol 32:5s, 2014 (suppl, abstr 2558).
32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027260)
33 ClinicalTrials.gov (NCT02258555) Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma. U.S. National Institutes of Health.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5196).
35 ClinicalTrials.gov (NCT02143635) Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt. U.S. National Institutes of Health.
36 ClinicalTrials.gov (NCT00708006) A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
37 ClinicalTrials.gov (NCT03344705) Safety and Efficacy Evaluation of IM19 Cells
38 ClinicalTrials.gov (NCT04811560) A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants With Acute Leukemia. U.S.National Institutes of Health.
39 ClinicalTrials.gov (NCT05424822) A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL. U.S.National Institutes of Health.
40 ClinicalTrials.gov (NCT05024045) A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. U.S.National Institutes of Health.
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034097)
42 Clinical pipeline report, company report or official report of Rigel.
43 ClinicalTrials.gov (NCT00559533) A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7744).
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029358)
46 Clinical pipeline report, company report or official report of TAKEDA
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027651)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034685)
49 2011 Pipeline of Seattle Genetics.
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6060).
51 The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9.
52 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5701).
53 MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies.Mol Biol Rep. 2012 Jul;39(7):7237-49. doi: 10.1007/s11033-012-1554-7. Epub 2012 Feb 4.
54 FMNL1 down-regulation suppresses bone metastasis through reducing TGF-1 expression in non-small cell lung cancer (NSCLC).Biomed Pharmacother. 2019 Sep;117:109126. doi: 10.1016/j.biopha.2019.109126. Epub 2019 Jul 12.
55 Runx1 Structure and Function in Blood Cell Development.Adv Exp Med Biol. 2017;962:65-81. doi: 10.1007/978-981-10-3233-2_5.
56 Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.Biochem Pharmacol. 2018 Aug;154:357-372. doi: 10.1016/j.bcp.2018.05.018. Epub 2018 Jun 1.
57 Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma.Blood. 2010 Apr 29;115(17):3559-69. doi: 10.1182/blood-2009-08-236760. Epub 2010 Feb 25.
58 Transcription and protein expression of mb-1 and B29 genes in human hematopoietic malignancies and cell lines.Leukemia. 1993 Dec;7(12):1939-47.
59 The interplay of CDK4 and CDK6 in melanoma.Oncotarget. 2019 Feb 15;10(14):1346-1359. doi: 10.18632/oncotarget.26515. eCollection 2019 Feb 15.
60 Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.Cancer Cell. 2009 Nov 6;16(5):413-24. doi: 10.1016/j.ccr.2009.09.029.
61 Expression of the fetal-oncogenic fibroblast growth factor-8/17/18 subfamily in human hematopoietic tumors.Biochem Biophys Res Commun. 2005 Sep 30;335(3):843-9. doi: 10.1016/j.bbrc.2005.07.153.
62 Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.Oncotarget. 2016 Oct 25;7(43):69124-69135. doi: 10.18632/oncotarget.11986.
63 The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-B and disruption of mitochondria-dependent pathways. Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.
64 HSPB8 is methylated in hematopoietic malignancies and overexpression of HSPB8 exhibits antileukemia effect.Exp Hematol. 2012 Jan;40(1):14-21. doi: 10.1016/j.exphem.2011.09.004. Epub 2011 Sep 10.
65 Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).Blood. 1998 Jun 15;91(12):4419-26.
66 Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.Blood. 2011 Jul 14;118(2):446-55. doi: 10.1182/blood-2010-07-294785. Epub 2011 May 19.
67 PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.J Clin Invest. 2009 Feb;119(2):362-75. doi: 10.1172/JCI33216. Epub 2009 Jan 19.
68 The RCK gene associated with t(11;14) translocation is distinct from the MLL/ALL-1 gene with t(4;11) and t(11;19) translocations.Cancer Res. 1992 Nov 1;52(21):6083-7.
69 Reassessing the role of C-MYB in tumorigenesis.Oncogene. 1999 May 13;18(19):3034-8. doi: 10.1038/sj.onc.1202728.
70 Why target PIM1 for cancer diagnosis and treatment?.Future Oncol. 2010 Sep;6(9):1461-78. doi: 10.2217/fon.10.106.
71 Downregulation of Pim-2 induces cell cycle arrest in the G(0)/G(1) phase via the p53-non-dependent p21 signaling pathway.Oncol Lett. 2018 Apr;15(4):4079-4086. doi: 10.3892/ol.2018.7865. Epub 2018 Jan 26.
72 Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population.Toxicology. 2013 May 10;307:12-6. doi: 10.1016/j.tox.2012.07.003. Epub 2012 Jul 16.
73 PRL-2 increases Epo and IL-3 responses in hematopoietic cells.Blood Cells Mol Dis. 2010 Apr 15;44(4):209-14. doi: 10.1016/j.bcmd.2010.02.013. Epub 2010 Mar 11.
74 The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells.Leukemia. 2003 Feb;17(2):366-78. doi: 10.1038/sj.leu.2402767.
75 Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.Mol Cell Biol. 2003 Aug;23(16):5738-54. doi: 10.1128/MCB.23.16.5738-5754.2003.
76 Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia.J Interferon Cytokine Res. 2013 Jan;33(1):34-42. doi: 10.1089/jir.2012.0062. Epub 2012 Oct 31.
77 The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.Blood. 2016 Mar 17;127(11):1438-48. doi: 10.1182/blood-2015-08-662635. Epub 2016 Jan 4.
78 Evaluation of CD43 expression in non-hematopoietic malignancies.Ann Diagn Pathol. 2017 Aug;29:23-27. doi: 10.1016/j.anndiagpath.2017.04.010. Epub 2017 Apr 26.
79 Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.Jpn J Cancer Res. 1998 Jul;89(7):712-8. doi: 10.1111/j.1349-7006.1998.tb03275.x.
80 TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.Oncotarget. 2017 Jan 3;8(1):863-882. doi: 10.18632/oncotarget.13273.
81 Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.Hum Mutat. 2018 Apr;39(4):579-587. doi: 10.1002/humu.23399. Epub 2018 Jan 19.
82 The expression of PRAME in chronic lymphoproliferative disorders.Leuk Res. 2003 May;27(5):393-6. doi: 10.1016/s0145-2126(02)00217-5.
83 JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.Cancer Cell. 2018 Nov 12;34(5):741-756.e8. doi: 10.1016/j.ccell.2018.10.008.
84 Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.J Clin Invest. 2016 Mar 1;126(3):905-20. doi: 10.1172/JCI84014. Epub 2016 Jan 25.
85 Serum SOX11 promoter methylation is a novel biomarker for the diagnosis of Hepatitis B virus-related hepatocellular carcinoma.Neoplasma. 2016;63(3):419-26. doi: 10.4149/311_151029N552.
86 TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair.Front Oncol. 2019 Apr 2;9:210. doi: 10.3389/fonc.2019.00210. eCollection 2019.
87 Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells: implication in the sensitivity to verotoxins.J Biol Chem. 2002 Mar 29;277(13):11247-54. doi: 10.1074/jbc.M109519200. Epub 2002 Jan 8.
88 NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.Cancer Cell. 2016 Dec 12;30(6):863-878. doi: 10.1016/j.ccell.2016.10.019. Epub 2016 Nov 23.
89 Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10years and future perspectives.Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13.
90 Chromatin Regulation by HP1 Contributes to Survival of 5-Azacytidine-Resistant Cells.Front Pharmacol. 2018 Oct 16;9:1166. doi: 10.3389/fphar.2018.01166. eCollection 2018.
91 CD109, a negative regulator of TGF- signaling, is a putative risk marker in diffuse large B-cell lymphoma.Int J Hematol. 2017 May;105(5):614-622. doi: 10.1007/s12185-016-2173-1. Epub 2016 Dec 28.
92 The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies.PLoS One. 2015 Nov 20;10(11):e0143275. doi: 10.1371/journal.pone.0143275. eCollection 2015.
93 Translocation (16;18)(p13;q21.3) in follicular lymphoma.Cancer Genet Cytogenet. 2004 Oct 15;154(2):160-2. doi: 10.1016/j.cancergencyto.2004.02.008.
94 Tumor cells of non-hematopoietic and hematopoietic origins express activation-induced C-type lectin, the ligand for killer cell lectin-like receptor F1.Int Immunol. 2010 Sep;22(9):783-90. doi: 10.1093/intimm/dxq430. Epub 2010 Jul 26.
95 Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.Clin Chem Lab Med. 2014 Dec;52(12):1859-65. doi: 10.1515/cclm-2014-0446.
96 DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma.Biochem Biophys Res Commun. 2010 Apr 23;395(1):111-5. doi: 10.1016/j.bbrc.2010.03.148. Epub 2010 Mar 27.
97 Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer.Cancer Res. 2016 Apr 1;76(7):1814-24. doi: 10.1158/0008-5472.CAN-14-3816. Epub 2016 Feb 26.
98 Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015 Feb;47(2):180-5. doi: 10.1038/ng.3177. Epub 2015 Jan 12.
99 Establishment of a transgenic mouse to model ETV7 expressing human tumors.Transgenic Res. 2019 Feb;28(1):115-128. doi: 10.1007/s11248-018-0104-z. Epub 2018 Nov 27.
100 A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.Cancer Genet. 2017 Oct;216-217:91-99. doi: 10.1016/j.cancergen.2017.07.007. Epub 2017 Aug 3.
101 GATA2 mutations in myeloid malignancies: Two zinc fingers in many pies.IUBMB Life. 2020 Jan;72(1):151-158. doi: 10.1002/iub.2204. Epub 2019 Nov 29.
102 Some implications of genetic biomarkers in occupational epidemiology and practice.Scand J Work Environ Health. 2004 Feb;30(1):71-9. doi: 10.5271/sjweh.767.
103 Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2007 Sep;13(9):1031-40. doi: 10.1016/j.bbmt.2007.05.010. Epub 2007 Jul 20.
104 Downregulation of Prdm16 mRNA is a specific antileukemic mechanism during HOXB4-mediated HSC expansion in vivo.Blood. 2014 Sep 11;124(11):1737-47. doi: 10.1182/blood-2013-10-534735. Epub 2014 Jul 31.
105 Aberrant DNA methylation of key genes and Acute Lymphoblastic Leukemia.Biomed Pharmacother. 2018 Jan;97:1493-1500. doi: 10.1016/j.biopha.2017.11.033. Epub 2017 Nov 20.
106 KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RAR.Cancer Cell Int. 2019 Oct 4;19:256. doi: 10.1186/s12935-019-0979-7. eCollection 2019.
107 L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability.Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22552-7. doi: 10.1073/pnas.1017092108. Epub 2010 Dec 13.
108 Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth.PLoS One. 2012;7(9):e44979. doi: 10.1371/journal.pone.0044979. Epub 2012 Sep 27.
109 High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.Int J Hematol. 2015 Dec;102(6):662-9. doi: 10.1007/s12185-015-1880-3. Epub 2015 Oct 8.
110 MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.Cell Rep. 2019 Sep 10;28(11):2851-2865.e4. doi: 10.1016/j.celrep.2019.07.095.
111 Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias.Leukemia. 1997 Apr;11 Suppl 3:358-60.
112 Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors.Int J Mol Med. 2006 Nov;18(5):917-23.
113 Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma.Blood. 2011 Feb 10;117(6):2005-8. doi: 10.1182/blood-2010-02-271460. Epub 2010 Dec 8.
114 Function of Nup98 subtypes and their fusion proteins, Nup98-TopII and Nup98-SETBP1 in nuclear-cytoplasmic transport.Biochem Biophys Res Commun. 2017 May 20;487(1):96-102. doi: 10.1016/j.bbrc.2017.04.024. Epub 2017 Apr 7.
115 Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells.Oncogene. 2009 Dec 10;28(49):4364-74. doi: 10.1038/onc.2009.288.
116 Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.Mod Pathol. 2019 Apr;32(4):490-498. doi: 10.1038/s41379-018-0165-9. Epub 2018 Nov 6.
117 PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.Blood. 2019 Apr 18;133(16):1729-1741. doi: 10.1182/blood-2018-07-860726. Epub 2019 Feb 12.
118 A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.Blood. 2013 Jun 6;121(23):4758-68. doi: 10.1182/blood-2012-06-435792. Epub 2013 Mar 13.
119 HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells.Oncogene. 2001 Aug 30;20(38):5373-7. doi: 10.1038/sj.onc.1204698.
120 SETDB1 modulates the differentiation of both the crystal cells and the lamellocytes in Drosophila.Dev Biol. 2019 Dec 1;456(1):74-85. doi: 10.1016/j.ydbio.2019.08.008. Epub 2019 Aug 15.
121 Splicing factor gene mutations in hematologic malignancies.Blood. 2017 Mar 9;129(10):1260-1269. doi: 10.1182/blood-2016-10-692400. Epub 2016 Dec 9.
122 Epigenetic regulator Smchd1 functions as a tumor suppressor.Cancer Res. 2013 Mar 1;73(5):1591-9. doi: 10.1158/0008-5472.CAN-12-3019. Epub 2012 Dec 26.
123 Splicing factor SRP20 is a novel partner of BCL6 in a t(3;6)(q27;p21) translocation in transformed follicular lymphoma.Genes Chromosomes Cancer. 2001 Nov;32(3):281-4. doi: 10.1002/gcc.1191.
124 Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL).Leuk Res. 2006 Jul;30(7):883-9. doi: 10.1016/j.leukres.2005.11.012. Epub 2006 Jan 6.
125 Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.Oncogene. 2013 May 16;32(20):2586-91. doi: 10.1038/onc.2012.263. Epub 2012 Jul 2.
126 Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells.Oncogene. 2007 May 31;26(26):3797-810. doi: 10.1038/sj.onc.1210152. Epub 2006 Dec 18.
127 BCR: a promiscuous fusion partner in hematopoietic disorders.Oncotarget. 2019 Apr 12;10(28):2738-2754. doi: 10.18632/oncotarget.26837. eCollection 2019 Apr 12.
128 Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.Hum Pathol. 2007 Mar;38(3):500-7. doi: 10.1016/j.humpath.2006.09.020.
129 EBP1 protein modulates the expression of human MHC class II molecules in non-hematopoietic cancer cells.Int J Oncol. 2015 Aug;47(2):481-9. doi: 10.3892/ijo.2015.3051. Epub 2015 Jun 16.